Deruxtecan
- 发布日期： 2022-07-26
- 更新日期： 2025-06-04
产品详请
| 产地 |
China
|
| 货号 |
CS00468
|
| 品牌 |
Chemstan
|
| 用途 |
Research Grade
|
| 型号 |
|
| 外观 |
|
| CAS编号 |
1599440-13-7
|
| 别名 |
德鲁替康
|
| 级别 |
其他
|
| 重金属 |
ppm
|
| 英文名称 |
Deruxtecan
|
| 包装规格 |
支
|
| 纯度 |
98%%
|
| 分子式 |
C52H56FN9O1
|
产品描述
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
靶点活性
Camptothecins
体外活性
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window[2].
别名
化合物Deruxtecan
纯度
98%
分子量
1034.05
分子式
C52H56FN9O13
CAS No.
1599440-13-7
存储
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
溶解度
DMSO: 34 mg/mL (32.88 mM)
H2O: < 0.1 mg/mL (insoluble)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
参考文献
1. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.
2. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
Note
For research use only .
